TD 1414

Drug Profile

TD 1414

Alternative Names: TD-1414

Latest Information Update: 27 Nov 2009

Price : $50

At a glance

  • Originator LEO Pharma
  • Class Antibacterials
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Skin and soft tissue infections

Most Recent Events

  • 23 Nov 2009 Discontinued - Phase-II for Skin and soft tissue infections in USA (Topical)
  • 23 Sep 2009 TD 1414 is no longer licensed to Warner Chilcott
  • 31 Dec 2008 TD 1414 is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top